ECSP088324A - 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas - Google Patents
2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onasInfo
- Publication number
- ECSP088324A ECSP088324A EC2008008324A ECSP088324A ECSP088324A EC SP088324 A ECSP088324 A EC SP088324A EC 2008008324 A EC2008008324 A EC 2008008324A EC SP088324 A ECSP088324 A EC SP088324A EC SP088324 A ECSP088324 A EC SP088324A
- Authority
- EC
- Ecuador
- Prior art keywords
- amino
- pyrido
- pyrimidine
- dihydro
- compounds
- Prior art date
Links
- CZOQBGHFZWUWPV-UHFFFAOYSA-N 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-one Chemical compound O=C1NCCC2=NC(N)=NC=C21 CZOQBGHFZWUWPV-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000005727 virus proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Los compuestos revelados son 2-amino-7,8-dihidro-6H-pirido[4,3-d]pirimidina-5-uno, sus estereoisómeros, tautómeros, sales aceptadas farmacéuticamente, y pro-medicamentos de lo mismo; las composiciones que incluyen un portador farmacéuticamente aceptable y uno o más de los compuestos 2-amino-7,8-dihidro-6H-pirido[4,3-d]pirimidina-5-uno, ya sea solos o en combinación con por lo menos un agente terapéutico adicional. Se revelan los métodos de uso de los compuestos 2-amino-7,8-dihidro-6H-pirido[4,3-d]pirimidina-5-uno, ya sea solos o en combinación con por lo menos un agente terapéutico adicional, en la profilaxis o tratamiento de las enfermedades del sistema nervioso central, cardiovasculares, autoinmune, virales, y de proliferación celular.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72279605P | 2005-09-30 | 2005-09-30 | |
| US83688606P | 2006-08-09 | 2006-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088324A true ECSP088324A (es) | 2008-04-28 |
Family
ID=37661234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008324A ECSP088324A (es) | 2005-09-30 | 2008-03-28 | 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7671059B2 (es) |
| EP (1) | EP1928875B1 (es) |
| JP (2) | JP5036002B2 (es) |
| KR (1) | KR101311757B1 (es) |
| AR (1) | AR058072A1 (es) |
| AT (1) | ATE514694T1 (es) |
| AU (1) | AU2006297124B2 (es) |
| BR (1) | BRPI0616701A2 (es) |
| CA (1) | CA2624253C (es) |
| CR (1) | CR9846A (es) |
| CY (1) | CY1112028T1 (es) |
| DK (1) | DK1928875T3 (es) |
| EA (1) | EA016152B1 (es) |
| EC (1) | ECSP088324A (es) |
| GE (1) | GEP20115231B (es) |
| HR (1) | HRP20110655T1 (es) |
| IL (1) | IL190446A0 (es) |
| JO (1) | JO2783B1 (es) |
| MA (1) | MA29885B1 (es) |
| ME (1) | ME01952B (es) |
| MY (1) | MY143604A (es) |
| NO (1) | NO342258B1 (es) |
| NZ (1) | NZ566914A (es) |
| PE (1) | PE20070621A1 (es) |
| PL (1) | PL1928875T3 (es) |
| PT (1) | PT1928875E (es) |
| RS (1) | RS51795B (es) |
| SM (1) | SMAP200800029A (es) |
| TN (1) | TNSN08143A1 (es) |
| TW (1) | TWI373471B (es) |
| WO (1) | WO2007041362A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| CN101225083A (zh) * | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 四氢喹唑啉酮类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| GB2449293A (en) | 2007-05-17 | 2008-11-19 | Evotec | Compounds having Hsp90 inhibitory activity |
| SG187502A1 (en) | 2008-02-01 | 2013-02-28 | Takeda Pharmaceutical | Oxim derivatives as hsp90 inhibitors |
| EP2334379A2 (en) | 2008-09-26 | 2011-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Host cell kinases as targets for antiviral therapies against hcv infection |
| EP2370103B1 (en) * | 2008-11-28 | 2016-03-23 | Novartis AG | Pharmaceutical combinations comprising an isoxazole derived hsp90-inhibitor and the her2 inhibitor trastuzumab |
| BRPI0924107A2 (pt) | 2008-11-28 | 2019-09-24 | Novartis Ag | inibidores de hsp90 para tratamento terapêutico |
| MA32934B1 (fr) * | 2008-11-28 | 2012-01-02 | Novartis Ag | Combinaisons inhibitrices hsp90 |
| AR075180A1 (es) * | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| MX2012004846A (es) * | 2009-10-29 | 2012-10-05 | Genosco | Inhibidores de cinasa. |
| WO2012104823A2 (en) | 2011-02-04 | 2012-08-09 | Novartis Ag | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases |
| RU2624493C2 (ru) | 2011-10-14 | 2017-07-04 | Новартис Аг | 2-КАРБОКСАМИД ЦИКЛОАМИНО ПРОИЗВОДНЫЕ МОЧЕВИНЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ Hsp90 ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ |
| ITTO20111013A1 (it) | 2011-11-03 | 2013-05-04 | Dac Srl | Composti farmaceutici |
| CN103664938A (zh) * | 2012-09-12 | 2014-03-26 | 山东亨利医药科技有限责任公司 | 含有嘧啶并环的syk抑制剂 |
| EP2916841A1 (en) | 2012-11-07 | 2015-09-16 | Novartis AG | Combination therapy |
| US9677907B2 (en) * | 2013-03-14 | 2017-06-13 | Itron Inc | Intelligent receptacle |
| GB201306610D0 (en) * | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| RU2657783C2 (ru) | 2013-09-30 | 2018-06-15 | Тайхо Фармасьютикал Ко., Лтд. | Комбинированная терапия с использованием азабициклосоединения для ракового заболевания |
| EP3189051A1 (en) * | 2014-09-02 | 2017-07-12 | Pierre Fabre Médicament | Isoquinolinone derivatives useful in the treatment of cancer |
| KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
| KR101653560B1 (ko) * | 2016-02-02 | 2016-09-12 | 한국화학연구원 | 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물 |
| RU2629599C1 (ru) * | 2016-09-28 | 2017-08-30 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ химиолучевого лечения опухолей прямой кишки и анального канала |
| KR20250007021A (ko) | 2017-06-09 | 2025-01-13 | 추가이 세이야쿠 가부시키가이샤 | N-치환 아미노산을 포함하는 펩타이드의 합성 방법 |
| CN115916752B (zh) * | 2020-06-26 | 2025-05-06 | 日本农药株式会社 | 芳基四氢吡啶衍生物或其盐类、和含有该化合物的杀虫剂及其使用方法 |
| EP4310084A4 (en) * | 2021-03-08 | 2025-06-25 | Jinan University | Pyridopyrimidine-based compound and use thereof |
| WO2026027375A1 (de) | 2024-07-29 | 2026-02-05 | Bayer Aktiengesellschaft | Hydroxy-dihydropyridinon carboxamide als schädlingsbekämpfungsmittel |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6165873A (ja) * | 1984-09-07 | 1986-04-04 | Mitsui Petrochem Ind Ltd | ２−ピペラジノピリミジン誘導体 |
| US4734418A (en) * | 1984-12-14 | 1988-03-29 | Mitsui Petrochemical Industries, Ltd. | Quinazoline compounds and antihypertensives |
| IL85347A0 (en) * | 1987-02-11 | 1988-07-31 | May & Baker Ltd | Cyclic diones |
| DE60206363T2 (de) * | 2001-02-12 | 2006-07-06 | F. Hoffmann-La Roche Ag | 6-substituierte pyridopyrimidine |
| DE102004018198A1 (de) * | 2004-04-15 | 2005-11-03 | Merck Patent Gmbh | Sulfonamide |
| WO2006045010A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| WO2006074293A2 (en) * | 2005-01-07 | 2006-07-13 | President And Fellows Of Harvard College | Bicyclic dihydropyrimidines as eg5 inhibitors |
| BRPI0609309A2 (pt) * | 2005-04-14 | 2010-03-09 | Novartis Vaccines & Diagnostic | 2-amino-quinazolin-5-onas como inibidores hsp90 com utilidade no tratamento de doenças proliferativas |
-
2006
- 2006-09-26 JO JO2006335A patent/JO2783B1/en active
- 2006-09-28 PL PL06825272T patent/PL1928875T3/pl unknown
- 2006-09-28 EP EP06825272A patent/EP1928875B1/en active Active
- 2006-09-28 CA CA2624253A patent/CA2624253C/en not_active Expired - Fee Related
- 2006-09-28 DK DK06825272.5T patent/DK1928875T3/da active
- 2006-09-28 ME MEP-2011-334A patent/ME01952B/me unknown
- 2006-09-28 AU AU2006297124A patent/AU2006297124B2/en not_active Ceased
- 2006-09-28 PT PT06825272T patent/PT1928875E/pt unknown
- 2006-09-28 RS RS20110334A patent/RS51795B/sr unknown
- 2006-09-28 SM SM200800029T patent/SMAP200800029A/it unknown
- 2006-09-28 KR KR1020087010134A patent/KR101311757B1/ko not_active Expired - Fee Related
- 2006-09-28 BR BRPI0616701-2A patent/BRPI0616701A2/pt not_active IP Right Cessation
- 2006-09-28 GE GEAP200610671A patent/GEP20115231B/en unknown
- 2006-09-28 AT AT06825272T patent/ATE514694T1/de active
- 2006-09-28 NZ NZ566914A patent/NZ566914A/en not_active IP Right Cessation
- 2006-09-28 WO PCT/US2006/038181 patent/WO2007041362A1/en not_active Ceased
- 2006-09-28 EA EA200800992A patent/EA016152B1/ru not_active IP Right Cessation
- 2006-09-28 JP JP2008533697A patent/JP5036002B2/ja not_active Expired - Fee Related
- 2006-09-28 MY MYPI20080862A patent/MY143604A/en unknown
- 2006-09-28 US US11/541,462 patent/US7671059B2/en active Active
- 2006-09-28 HR HR20110655T patent/HRP20110655T1/hr unknown
- 2006-09-28 PE PE2006001177A patent/PE20070621A1/es not_active Application Discontinuation
- 2006-09-28 AR ARP060104292A patent/AR058072A1/es unknown
- 2006-09-29 TW TW095136162A patent/TWI373471B/zh not_active IP Right Cessation
-
2008
- 2008-03-26 IL IL190446A patent/IL190446A0/en not_active IP Right Cessation
- 2008-03-28 EC EC2008008324A patent/ECSP088324A/es unknown
- 2008-03-28 TN TNP2008000143A patent/TNSN08143A1/en unknown
- 2008-03-28 CR CR9846A patent/CR9846A/es unknown
- 2008-04-24 MA MA30873A patent/MA29885B1/fr unknown
- 2008-04-30 NO NO20082069A patent/NO342258B1/no not_active IP Right Cessation
-
2009
- 2009-07-31 US US12/462,302 patent/US20100004237A1/en not_active Abandoned
-
2011
- 2011-08-09 CY CY20111100758T patent/CY1112028T1/el unknown
-
2012
- 2012-05-25 JP JP2012119613A patent/JP2012158611A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088324A (es) | 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas | |
| SV2008002856A (es) | 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas | |
| CR8891A (es) | Antagonismo de la actividad del receptor de interleuquina 21 | |
| TNSN06071A1 (en) | Use of modified cyclosporins for the treatment of hcv disorders | |
| ECSP055640A (es) | Composiciones de pirazol útiles como inhibidores de gsk-3 | |
| CL2007002062A1 (es) | Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
| UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
| CR9591A (es) | Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina | |
| UY26482A1 (es) | Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales | |
| CL2008001540A1 (es) | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2008002852A1 (es) | Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas. | |
| BRPI0510170B8 (pt) | composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto | |
| UY29246A1 (es) | Nuevos compuestos | |
| BRPI0616630B8 (pt) | compostos de pirazol substituídos | |
| ECSP045410A (es) | Nuevos derivados de piridazin-3(2h)-ona | |
| MXPA06001134A (es) | Inhibidores de la actividad de la proteina cinasa b. | |
| CR6577A (es) | Inhibidores triciclicos de poli(adp-ribosa) polimerasas | |
| CL2007001710A1 (es) | Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras. | |
| CO6382131A2 (es) | Derivados de tieno [3,2-c]piridina como inhibidores de quinasas para el uso en el tratamiento del cáncer | |
| CL2008003659A1 (es) | Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad. | |
| ATE430746T1 (de) | Crf-rezeptor-antagonisten und zugehörige verfahren | |
| NO20074780L (no) | Heterocyklylamidsubstituerte imidazoler | |
| PL1899334T3 (pl) | Związki naftyrydynowe | |
| SI1841765T1 (sl) | Imidazo(4,5-c)piridinska spojina in postopek za antivirusno zdravljenje | |
| NO20053903L (no) | Nukleotidlipidesterderivater. |